aRCC: 1L Treatment Options and Patient Management

Moffitt Cancer Center
J

Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy in Genitourinary Malignancies

By Moffitt Cancer Center FEATURING Jianjun Gao
By Moffitt Cancer Center FEATURING Jianjun Gao
248 views
August 25, 2022
Comments 0
Login to view comments. Click here to Login
12:14

ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…

ASCO Genitourinary Cancers Symposium

S. Tykodi

181 views
08:40

Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …

Thomas Hutson

98 views
16:00

ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma

ASCO Genitourinary Cancers Symposium

M. Dean

190 views
09:23

ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …

ASCO Genitourinary Cancers Symposium

R. McKay

77 views
16:34

ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…

ASCO Genitourinary Cancers Symposium

N. Haas

144 views
06:04

ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA-4 B…

ASCO 2022 Conference Coverage

L. Albiges

139 views
13:28

2022 ASCO Renal Cell Carcinoma Updates

Total Health

M. Bupathi

198 views
12:53

Dual Immunotherapy in RCC

O'Neal Comprehensive Cancer Center at UAB

A. Basu

548 views
20:47

ESMO 2022 on the Latest in mRCC

ecancer

J. Puente, B. Escudier, V. Grünwald, S. Oudard

195 views
21:09

Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…

Mário Fontes-Sousa

228 views
20:23

Choosing Wisely: 1L Combination Treatment for Advanced RCC

Aly-Khan A. Lalani

749 views
06:50

ESMO 2022 Updates in Renal Cancer

ecancer

T. Choueiri

292 views
19:41

How I Manage Immune Adverse Events in Solid Tumors

Balazs Halmos

1.9K views
10:55

Systemic Therapies for Clear Cell RCC: Where Are We Now?

Yale Cancer Center

D. Braun

468 views
14:14

GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…

PrecisCa

M. Rettig, S. Slovin, T. Fraum, J. Abel, P. Patel

204 views